Official source Data mirrored from Centers for Medicare & Medicaid Services Open Payments · General Payments · CMS publication 2026-06-30 View official record

Covered recipient · General Payments record

MEGAN L MACKENZIE

Allopathic & Osteopathic Physicians Psychiatry & Neurology Neurology

NPI
1912274994
CMS profile
1382359
Location
CENTERVILLE, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

Saved items

Saved only in this browser. No account or alerts.

Filter and download payment records

General Payments · PY2021 · Entire year

$20,713.47

232 records · 0 disputed

Summary and payment records

  • CMS publication 2026-06-30
Read the payment records

“Financial relationships do not necessarily indicate an improper relationship; the data is open to interpretation.”

— Centers for Medicare & Medicaid Services, Open Payments

A reported payment reflects a financial relationship a company disclosed. It does not indicate wrongdoing or a conflict of interest, and it says nothing about the quality of a provider's care.

These records are submitted to CMS and attested to by the reporting companies. CMS publishes them as reported; this site mirrors them without independent verification.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

How these totals are calculated
  • This total is the sum of the individual General Payments record amounts CMS published for the labeled program year(s); each record amount is used unmodified. The total itself is computed by this site. Nothing is estimated, weighted, or combined across categories.
  • General Payments only. Research and Ownership/Investment are separate datasets and are never summed with these figures; amounts are kept separate per program year.
  • Methodology & Data — sourcing, labeling, and limitations.

Provider summaries generated . CMS updates this data on an annual cycle, and corrections or successful disputes made at CMS may not yet appear here. The official CMS record is authoritative for the current state. View the official CMS record ↗

By nature of payment

PY2021 · entire year · sorted by reported total

By paying entity

PY2021 · entire year · sorted by reported total

Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. Use the CSV download for all matching records.

IndustryPayments · General Payments

MEGAN L MACKENZIE

NPI 1912274994 · CMS profile ID 1382359

Allopathic & Osteopathic Physicians / Psychiatry & Neurology / Neurology

CENTERVILLE, OH

A name match is not confirmation of identity. CMS publishes records for different people under similar names; the NPI, specialty, and location shown on this page are the CMS-published fields that distinguish them.

A payment attributed to a provider may have been made to a third party — a hospital, practice, or research institution — rather than paid to the provider personally.

General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types

Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00

Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export.

Filtered page: https://industrypayments.org/provider/npi-1912274994?year=2021&recipient=provider&page=2#records-h

CMS source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202

Cite these filtered records

The citation includes this program year, filters, data edition, and page of results.

Plain
MEGAN L MACKENZIE, NPI 1912274994, CMS profile ID 1382359. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. IndustryPayments. https://industrypayments.org/provider/npi-1912274994?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
APA 7
IndustryPayments. (2026). MEGAN L MACKENZIE, NPI 1912274994, CMS profile ID 1382359. General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types. Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00. Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. [Filtered data set page]. https://industrypayments.org/provider/npi-1912274994?year=2021&recipient=provider&page=2#records-h. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202.
Bluebook
MEGAN L MACKENZIE, NPI 1912274994, CMS profile ID 1382359, IndustryPayments, General Payments, PY2021; Recipient scope: Physicians and non-physician practitioners; Reporting company: All reporting companies; Nature of payment: All payment types (Data edition: cms-20260630-workflow-20261105-v2; CMS publication: 2026-06-30; records imported: 2026-11-05T09:06:52.159882+00:00). Page 2 of 5; records 51–100 of 232 matching records. This page contains 50 records (maximum 50), not the full filtered export. Source: https://openpaymentsdata.cms.gov/dataset/0380bbeb-aea1-58b6-b708-829f92a48202. https://industrypayments.org/provider/npi-1912274994?year=2021&recipient=provider&page=2#records-h.

Centers for Medicare & Medicaid Services, Open Payments

Citation formats are provided for reference; check the requirements of your publication.

Payment records · PY2021

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

General Payments · PY2021 · Physicians and non-physician practitioners · CMS publication 2026-06-30

232 matching records · $20,713.47 reported total · 0 disputed

Nature of payment: All payment types

Records imported here (UTC).

Link to these filtered records · CMS source dataset ↗

Download all 232 matching records (CSV)

CSV includes CMS record IDs, source and publication dates, the data edition, and a link to these filters. Formula-like text cells are prefixed with an apostrophe for spreadsheet safety.

Showing records 51–100 of 232.

Paying entityAmountDate Nature of paymentDispute statusPublication flagsPublished Record IDSource
Novartis Pharmaceuticals Corporation $9.8110/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813043769 CMS
Biohaven Pharmaceuticals, Inc. $15.3310/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852555585 CMS
AbbVie Inc. $15.5710/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795427673 CMS
Allergan, Inc. $7.3410/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792860023 CMS
Biogen, Inc. $20.6710/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 827848007 CMS
GENZYME CORPORATION $17.4710/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843698399 CMS
HARMONY BIOSCIENCES LLC $11.9610/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 853081457 CMS
Supernus Pharmaceuticals, Inc. $12.5910/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 845075347 CMS
Teva Pharmaceuticals USA, Inc. $8.1910/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 839574489 CMS
Lilly USA, LLC $1,400.0009/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818611123 CMS
Lilly USA, LLC $525.0009/30/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818641533 CMS
Amgen Inc. $6.9909/29/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825605969 CMS
AbbVie Inc. $12.9609/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795427667 CMS
Lilly USA, LLC $12.0009/28/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818669305 CMS
SK Life Science, Inc. $11.2909/27/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826825511 CMS
EMD Serono, Inc. $20.7709/24/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849211115 CMS
Lilly USA, LLC $700.0009/24/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818641531 CMS
Lilly USA, LLC $700.0009/22/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818651311 CMS
Biohaven Pharmaceuticals, Inc. $2,250.0009/14/2021 Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852555581 CMS
Biohaven Pharmaceuticals, Inc. $80.1609/14/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852555583 CMS
Novartis Pharmaceuticals Corporation $14.5509/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813043765 CMS
Adamas Pharmaceuticals, Inc. $15.2709/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834401297 CMS
SK Life Science, Inc. $21.3709/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826825507 CMS
Lilly USA, LLC $10.9209/08/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818641543 CMS
Allergan, Inc. $15.0509/07/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792860021 CMS
AbbVie Inc. $9.9009/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795427661 CMS
Greenwich Biosciences, Inc. $17.5309/03/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 841830951 CMS
Amgen Inc. $21.6109/01/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825605965 CMS
AbbVie Inc. $2.8008/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795427655 CMS
GENZYME CORPORATION $18.0008/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843698389 CMS
Novartis Pharmaceuticals Corporation $8.1608/31/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813043761 CMS
Acorda Therapeutics, Inc $16.4208/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792555073 CMS
Neurelis, Inc. $15.2008/30/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842871985 CMS
Lilly USA, LLC $8.3408/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 818669307 CMS
SK Life Science, Inc. $20.7208/25/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 826825501 CMS
AbbVie Inc. $9.4408/23/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795427649 CMS
Amgen Inc. $13.1008/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825605957 CMS
Biohaven Pharmaceuticals, Inc. $16.1708/19/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 852555579 CMS
Adamas Pharmaceuticals, Inc. $14.0908/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 834401295 CMS
Amgen Inc. $14.2408/18/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825605953 CMS
AbbVie Inc. $1.2908/17/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 795427643 CMS
Allergan, Inc. $15.0508/16/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 792860019 CMS
Neurelis, Inc. $14.4908/13/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 842871981 CMS
UCB, Inc. $16.6108/12/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807317055 CMS
EMD Serono, Inc. $23.4408/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 849204685 CMS
GENZYME CORPORATION $14.7308/11/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 843698385 CMS
Janssen Pharmaceuticals, Inc $18.5308/10/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 788814683 CMS
Novartis Pharmaceuticals Corporation $6.9508/06/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 813043757 CMS
UCB, Inc. $13.0008/05/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 807383461 CMS
Amgen Inc. $7.0408/04/2021 Food and Beverage No dispute reported Delay: No
Change: UNCHANGED
06/30/2026 825605949 CMS

By program year

All program years on this page · sorted by year

Program yearAmountRecords
PY2019 $11,798.97 262
PY2020 $12,722.50 158
PY2021 $20,713.47 232
PY2022 $8,910.61 156
PY2023 $2,322.29 125
PY2024 $3,090.82 136
PY2025 $4,322.09 134

Source & provenance

Dataset
CMS Open Payments — General Payments
Publisher of source data
Centers for Medicare & Medicaid Services
CMS publication date
2026-06-30
Program years on this page
2019, 2020, 2021, 2022, 2023, 2024, 2025
Source files and profile matching
Generated from
OP_DTL_GNRL_PGYR2025_P06302026_06032026.csv

One page per canonical provider; split Profile_IDs are merged via Associated_Covered_Recipient_Profile_ID_1/_2 from the Covered Recipient Profile Supplement.

Corrections to the substance of a record route to CMS through its review-and-dispute process; errors in how this site mirrors or displays a record route to us. Both paths are described in Methodology & Data.

Research Payments

One row per program year and role, newest year first · amounts for the two roles are never added together

Program yearRoleAmountRecords
PY2025 Principal investigator $16,173.50 27
PY2024 Principal investigator $15,012.50 25
PY2023 Principal investigator $3,596.00 16
PY2022 Principal investigator $7,953.60 7
PY2021 Principal investigator $7,142.40 7
PY2020 Principal investigator $3,422.70 3

Research Payments are a separate CMS dataset, shown here separately and never added to General Payments. A research payment is often made to an institution, with this provider named as a principal investigator; each record states which role applies.

“If you are a physician who served as a principal investigator on a research study, you may see the payments associated with that research study listed under your name. This does not necessarily mean the payments are attributed to you. The dollar amount of the record corresponds to the total payment; the amounts are not attributed to each individual on the record.”

— Centers for Medicare & Medicaid Services, Open Payments Frequently Asked Questions, FAQ #12224

Research Payments records · PY2025

Ordering applied by this site (date, newest first, then paying entity) · record values are shown as CMS published them

27 records in PY2025

Research Payments records (CSV)

RolePaying entityAmount DateRecipientStudy Dispute statusPublishedRecord ID
Principal investigator 1 PFIZER INC. $10,083.00 11/07/2025 Non-covered Recipient Entity
Dayton Center for Neurological Disorders
AN INTERVENTIONAL EFFICACY AND SAFETY PHASE 3 DOUBLEBLIND PARALLEL GROUP STUDY TO INVESTIGATE INTERMITTENT PREVENTION OF MENSTRUAL MIGRAINE WITH RIMEGEPANT COMPARED WITH PLACEBO IN WOMEN PARTICIPANTS 18 TO 45 YEARS OF AGE No dispute reported 06/30/2026 1228739081
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595809
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595813
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595819
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595823
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595827
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595832
Principal investigator 1 Roche Products Limited $235.00 09/24/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595836
Principal investigator 1 Roche Products Limited $70.50 09/24/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595840
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595765
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595770
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595774
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595779
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595783
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595787
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595791
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595795
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595800
Principal investigator 1 Roche Products Limited $235.00 06/25/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595804
Principal investigator 1 UCB SA $380.00 04/01/2025 Non-covered Recipient Entity
Dayton Center For Neurological Disorders
A MULTICENTER PHASE 2, DOUBLE-BLIND, PLACEBO-CONTROLLED, RANDOMIZED, PARALLEL GROUP STUDY TO EVALUATE THE EFFICACY, SAFETY, TOLERABILITY, AND PHARMACOKINETICS OF UCB0022 IN STUDY PARTICIPANTS WITH ADVANCED Parkinsons DISEASE No dispute reported 06/30/2026 1246656646
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595739
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595757
Principal investigator 1 Roche Products Limited $235.00 03/24/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595761
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595734
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595744
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595748
Principal investigator 1 Roche Products Limited $235.00 01/09/2025 Non-covered Recipient Entity
DAYTON CENTER FOR NEUROLOGICAL DISORDERS
Observational Study of Ocrelizumab treated Multiple Sclerosis Patients US commitment No dispute reported 06/30/2026 1211595752